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www.cdatm.orgAbstractObjective: Metabolic syndrome (MS) is a combination of medical disorders that increase the risk for cardiovascular disease and
diabetes mellitus. It suggests an association between an elevated serum aminotransferase level and MS. Little data show the
relationship between the levels of serum aminotransferase and the incidence of MS in Ningxia, China.
Methods: A total of 5415 subjects who received medical health checkups from 2007 to 2009 were enrolled in the study. The
participants were interviewed by trained health workers under a structured questionnaire. MSwas defined according to the modified
ATPIII criteria for Asian Americans by the American Heart Association (AHA-ATP III).
Results: The prevalence of elevated aspartate aminotransferase (AST) and ALT (>40 U/L) were 7.1% and 22.2% in males,
and 2.1% and 4.8% in females respectively. The prevalence of MS was 32.1% in males and 15.4% in females. The components
of MS were significantly more in the group with elevated aminotransferase levels than in the group with normal amino-
transferase levels. The odds ratios (95% CI) for elevated AST were 1.90 (1.49, 2.42), 2.59 (2.01, 3.39), 1.68 (1.32, 2.15), and
1.81 (1.36, 2.42) in the adults with abdominal obesity, high serum triglycerides levels, high blood pressure, and high plasma
glucose levels respectively. After adjustment for age, the odds ratios (95% CI) for elevated ALT were 3.08 (2.63, 3.61), 4.30
(3.64, 5.08), 1.26 (1.08, 1.48), 2.16 (1.93, 2.65) and 2.38 (1.96, 2.87) in adults with abdominal obesity, high serum tri-
glycerides levels, low serum high-density lipoproteincholesterol (HDL-C), high blood pressure, and high plasma glucose
levels respectively. The odds ratios (95% CI) for elevated AST were 1.67 (1.06, 2.63), 2.28 (1.46, 3.63), 2.59 (1.59, 4.21) and* Corresponding author. 1160 Shengli Street, Xingqing District,
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125K.-P. He et al. / Chronic Diseases and Translational Medicine 1 (2015) 124e132for elevated ALT 2.02 (1.50, 2.73), 2.68 (1.96, 3.65), 3.94 (2.86, 5.43) for the subjects with 1, 2, and 3 risk factors after
adjustment for age, gender, and BMI.
Conclusion: The serum aminotransferase levels were higher in males compared to females, and serumALT level was more closely
associated with MS than the AST level in adults in Ningxia, China. With an increasing the number of components of MS, the
aminotransferase levels and the risks for elevated aminotransferase increase, whereas the AST/ALT ratios decrease.
© 2015 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Metabolic syndrome (MS) is a combination of
metabolic disorders, such as dyslipidemia, hyperten-
sion, impaired glucose tolerance, compensatory hyper-
insulinemia and the tendency to develop fat around the
abdomen.1 Consequently, people with MS are at high
risk of atherosclerosis and cardiovascular disease.
Liver enzymes are used most commonly in labora-
tory tests, and are the key to the laboratory evaluation
of liver damage. Several studies reported that liver
enzymes might be associated with MS through many
metabolic disorders such as overweight and obesity,
dyslipidemia, diabetes (DM), and hypertension, while
insulin resistance was considered as the main cause.2e4
Alanine aminotransferase (ALT), a marker of fatty
liver, has been reported as an independent risk factor of
MS, diabetes, and cardiovascular diseases.5,6 Elevated
serum ALT levels have a positive correlation with MS-
related diseases, such as type 2-DM and cardiovascular
disease.7,8
Although there have been many studies regarding to
hypertension, obesity, diabetes, dyslipidemia, impaired
glucose tolerance, and MS in China,9e11 few studies
directly examined the correlation between MS and
aspartate aminotransferase (AST) or ALT in China,
especially in the relatively un-developed areas such as
Ningxia. Therefore, in this study, we focus on the role
of elevated aspartate and alanine aminotransferases on
MS and its components among adults living in Ning-
xia, China.
Methods
People and materials
The study population was selected from the em-
ployees of the local governments and industries who
visited the General Hospital of Ningxia Medical Uni-
versity, Ningxia, China, for medical health checkups,during 2007 and 2009 using stratified cluster sampling.
During the study period, 5415 subjects (age 20e78
years old, 3318 males and 2097 females) who did not
have any clinical evidence for cardiovascular disease
were randomly selected to participate in the study. The
subjects had no reported chronic viral infection, cold or
flu, acute respiratory infection, dental problems, or any
type of surgery during the study. All participants were
interviewed by trained investigators with a standard
closed-ended questionnaire.
The study protocol was approved by the Medical
Ethics Review Committee of Ningxia Medical Uni-
versity and there were no activities in the study that
violated ethical policies in China. All participants gave
consent to enrollment after they received written and
verbal information.
Anthropometric and biochemical measurements
Anthropometric measurements including height,
weight, and waist and hip circumference were
measured by well-trained examiners. Standing height
was measured once to the nearest 0.5 cm using a
portable ruler (made in China), body weight was also
measured once to the nearest 0.1 kg using a weight
scale (made in China). Body mass index (BMI) was
calculated as kg/m2. Waist circumference (WC) was
measured to the nearest 0.1 cm at the midpoint be-
tween the lower borders of the rib cage and the iliac
crest and the hip circumference (HC) was measured to
the nearest 0.1 cm at the point about 1 cm above the
navel. All measurements were performed by the study
investigators. Blood pressure was also recorded after at
least 10 minutes of rest in a chair, with feet on the
floor, and arm supported at heart level, using a mercury
sphygmomanometer. Patients with average blood
pressure 140/90 mmHg or taking antihypertensive
medication were classified as hypertensive. Blood
samples of 5 ml were collected from the antecubital
vein between 7 and 9 AM, after 10 hours of fasting and
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implied by fasting). Total cholesterol, triglyceride,
serum glucose, high density lipoprotein (HDL)
cholesterol, low density lipoprotein (LDL) cholesterol,
AST, and ALT levels were measured by an auto-
analyzer (Olympus AU2700, Japan).
Definition of elevated serum aminotransferase and meta-
bolic syndrome
Both elevated AST and ALT are defined as when the
enzyme activity is higher than 40 U/L, similar to
thresholds that have been previously used in stud-
ies.12e15 MS was defined according to the modified
ATPIII criteria for Asian Americans by the American
Heart Association (AHA-ATP III). In the present study,
individuals having three or more among the five
following metabolic components were defined as
having the MS: waist circumference 90 cm for men
or 80 cm for women, triglyceride level1.7 mmol/L,
HDL-cholesterol level <1.03 mmol/L for males or
<1.3 mmol/L for females, blood pressure 130/
85 mmHg or antihypertensive medication, fasting
blood glucose 5.6 mmol/L or on drug treatment for
elevated glucose.16
Statistical analysis
Data are presented as mean values with standard
deviations for continuous variables and as absolute and
relative frequencies or prevalence for categorical var-
iables. Comparisons between two groups were per-
formed with Pearson c2 tests for categorical variables,
and Student's t-tests for continuous variables. TheTable 1
The prevalence of elevated AST levels, elevated ALT levels, and MS in the
Age Elevated AST (%) Elevated ALT (%
Male Female Male
20～ 9.2 (38/414)b 1.5 (6/401)a,b 26.1 (108/414)b
30～ 8.4 (80/947) 1.2 (9/727)a 28.0 (265/947)
40～ 7.4 (80/1085) 2.1 (13/622)a 23.9 (259/1085)
50～ 4.8 (27/599) 4.3 (10/230) 14.3 (80/559)
60～ 3.2 (10/313) 6.0 (7/117) 7.7 (24/313)
overall 7.1 (235/3318) 2.1 (45/2097)a 22.2 (736/3318)
AST: aspartate aminotransferase; ALT: alanine aminotransferase; MS: met
serum ALT >40 U/L and MS versus total subject number in different age g
a Significantly different from the female group are males with elevated AS
21.422, 63.862; 81.707, 163.540, 100.003, 5.436, 296.520; 23.193, 99.594, 8
c2 test).
b Significantly different from different age groups with elevated AST, elev
138.167; 17.183, 9.655, 299.696; respectively, all P < 0.05 or P < 0.01.relationships among serum aminotransferase and other
continuous variables were analyzed using Spearman's
rank correlations. The general linear model was used to
test the linear trend of serum aminotransferase levels
according to the number of components of the MS.
Logistic regression analysis was performed to detect
the risks of elevated serum aminotransferase according
to the presence of each component of the MS. The
adjusted odds ratios (ORs) for elevated serum amino-
transferase according to the number of components of
the MS after adjustment for age, gender, and BMI are
presented together with their 95%CIs. The linear trend
in odds ratios was evaluated by using the trend test. All
reported P values were two-sided, and a P value less
than 0.05 was considered statistically significant. All
data were input into EpiData first and then exported
into SPSS version 14.0 (SPSS Corp, College Station,
NX).
Results
The incidence of elevated levels of AST, elevated
ALT and MS in the study population were presented in
Table 1. The incidence of elevated AST, elevated ALT,
and MS were 7.1%, 22.2%, and 32.1% for males and
2.1%, 4.8%, and 15.4% for females, respectively. The
overall elevated AST, ALT, and MS were more in
males than females. The incidence of elevated AST and
ALT decreased with age in males and increased in
females. The incidence of MS increased with age in
both males and females.
Of the study participants, 3318 (61.3%) were males
and 2097 (38.7%) were females. The levels of AST,
ALT, and AST/ALT, grouped by age and gender, werestudy population.
) MS (%)
Female Male Female
3.5 (14/401)a,b 12.3 (51/414)b 3.2 (13/401)a,b
4.0 (29/727)a 26.0 (246/947) 7.2 (52/727)a
5.0 (31/622)a 38.9 (422/1085) 18.3 (114/622)a
8.3 (19/230)a 41.3 (231/599) 33.9 (78/230)
6.8 (8/117) 36.4 (114/313) 56.4 (66/117)a
4.8 (101/2097)a 32.1 (1064/3318) 15.4 (323/2097)a
abolic syndrome. The number of subject with serum AST >40 U/L,
roups based on gender is displayed in brackets.
T, elevated ALT and MS in different age groups, c2¼ 23.540, 42.468,
0.240, 13.981, 189.611; respectively, all P < 0.05 or P < 0.01 (Pearson
ated ALT and MS in the male and female group, c2¼ 17.084, 82.173,
127K.-P. He et al. / Chronic Diseases and Translational Medicine 1 (2015) 124e132shown in Table 2. The overall mean values of AST
levels were higher in males than females
(25.49 ± 10.88 U/L vs. 20.84 ± 8.09 U/L, t ¼ 16.841,
P < 0.001). Similarly, the ALT levels were also higher
in males (31.40 ± 22.03 vs. 18.17 ± 13.52 U/L,
t ¼ 24.660, P < 0.001). The AST/ALT ratio was lower
in males (0.99 ± 0.80 vs. 1.37 ± 0.71, t ¼ 17.530
P < 0.001). The mean values of AST and ALT
decreased with age in males and increased in females.
The baseline characteristics of all subjects, with and
without MS, based on gender are shown in Table 3.
After adjustment for age, the mean values of BMI,
WC, systolic blood pressure, diastolic blood pressure,
triglycerides, AST, and ALT were higher in males than
in females. Females had higher levels of HDL
cholesterol and AST/ALT ratio males. Both males and
females with MS were more likely to be older in-
dividuals, with a higher BMI, WC, systolic blood
pressure, diastolic blood pressure, triglycerides, total
cholesterol, and plasma glucose. Higher AST and ALT
concentrations and lower AST/ALT ratio were found in
both males and females with MS.
As shown in Table 4, 5.2% and 15.5% of the par-
ticipants had elevated AST and ALT levels, respec-
tively. The subjects with elevated AST and ALT levels
had higher mean BMI, WC, systolic blood pressure,
diastolic blood pressure, triglycerides, total cholesterol,
and LDL cholesterol than the subjects with normal
AST and ALT levels. Age, HDL cholesterol, and
plasma glucose levels were not significantly different
between the normal AST group and the elevated AST
group. The subjects with elevated ALT levels were
significantly older and had a higher plasma glucose
level and significantly lower HDL cholesterol than the
subjects with normal ALT levels.
The correlation between each metabolic component
and the risk of elevated AST and ALT were shown inTable 2
The levels of AST, ALT, and AST/ALT grouped by age and gender.
AST ALT
Male Female Male
20～ 26.37 ± 12.36b 19.74 ± 6.56a,b 34.27 ± 28.19
30～ 26.19 ± 11.76 20.06 ± 7.10a 34.22 ± 24.21
40～ 25.66 ± 10.89 20.84 ± 8.34a 32.49 ± 21.71
50～ 24.42 ± 9.01 23.53 ± 10.91 27.27 ± 14.15
60～ 23.51 ± 8.39 24.19 ± 8.81 21.96 ± 13.15
overall 25.49 ± 10.88 20.84 ± 8.09 31.40 ± 22.03
AST: aspartate aminotransferase; ALT: alanine aminotransferase.
a Significantly different from the female group are male AST, ALTand AST
14.344, 3.631; 13.627, -8.921, -9.590, -5.988, -2.225; respectively, all P < 0
b Significantly different from different age groups with AST, ALTand AST
11.773, 6.341; respectively, all P < 0.01.Table 5. The percentage based on gender, BMI,
abdominal obesity, high serum triglycerides, high
blood pressure, and high plasma glucose were signifi-
cantly different between the normal and elevated
groups for both AST and ALT, whereas age and the
proportion with low serum HDL-C was only signifi-
cantly different for the elevated ALT group and normal
ALT group. Overall, males had a 3.48 (2.51e4.85) fold
risk of developing elevated AST levels compared to
females. The odds ratio for BMI (BMI 24e27.9: OR
1.96, 95%CI: 1.50e2.57; BMI 28: OR ¼ 3.77, 95%
CI: 2.69e5.30), abdominal obesity (OR ¼ 1.90, 95%
CI: 1.49e2.42), high triglycerides (OR ¼ 2.59, 95%CI:
2.01e3.39), high blood pressure (OR ¼ 1.68, 95%CI:
1.32e2.15) and high plasma glucose (OR ¼ 1.81, 95%
CI: 1.36e2.42) in the subjects were significantly
associated with elevated AST, whereas only the low
serum HDL-C was not significantly associated. After
adjustment of age, males had a 6.23 (5.01e7.75) fold
risk of developing elevated ALT levels compared to
female. The odds ratio for BMI (BMI 24e27.9: OR ¼
3.63, 95%CI: 3.05e4.33; BMI 28: OR 6.88, 95%CI:
5.46e8.69), abdominal obesity (OR ¼ 3.08, 95%CI:
2.63e3.61), high triglycerides (OR ¼ 4.30, 95%CI:
3.64e5.08), low serum HDL-C (OR ¼ 1.26, 95%CI:
1.08e1.48), high blood pressure (OR ¼ 2.16, 95%CI:
1.93e2.65), and high plasma glucose (OR ¼ 2.38, 95%
CI: 1.96e2.87) in the subjects were significantly
associated with elevated ALT after adjustment of age.
The relationship between the clustering of MS
components and the risk of elevated AST and ALT in
the participants are shown in Table 6. Consistent with
the above observations, AST and ALT increased pro-
gressively with an increasing number of MS compo-
nents. Levels of AST and ALT increased from
21.11 ± 9.4 U/L and 18.84 ± 17.92 U/L without any
MS component to 26.15 ± 11.33 U/L andAST/ALT
Female Male Female
b 16.21 ± 16.34a,b 0.99 ± 0.54b 1.48 ± 0.49a,b
16.85 ± 10.65a 0.96 ± 1.21 1.39 ± 0.58a
18.84 ± 12.61a 0.94 ± 0.64 1.32 ± 1.03a
22.64 ± 17.09a 1.02 ± 0.43 1.21 ± 0.41a
20.70 ± 13.07 1.22 ± 0.40 1.32 ± 0.41a
18.17 ± 13.52 0.99 ± 0.80 1.37 ± 0.71
/ALT in different age groups, t¼ 9.519, 12.435, 9.549; 1.327, 18.046,
.05 or P < 0.01 (Student's t-test).
/ALT in the male and female group, F¼ 5.708, 26.752, 8.495; 15.365,
Table 3
Baseline characteristics of all subjects with and without the metabolic syndrome.
Variables Metabolic syndrome Non metabolic syndrome
Male (n ¼ 1064) Female (n ¼ 323) Male (n ¼ 2254) Female (n ¼ 1774)
Age (years) 45.88 ± 10.78a,c 48.85 ± 11.63c 41.70 ± 12.02a 37.80 ± 9.59
BMI (kg$m2) 26.59 ± 2.68b,d 24.73 ± 2.72d 23.74 ± 2.81b 21.28 ± 2.58
WC (cm) 94.08 ± 6.21b,d 84.18 ± 7.84d 84.70 ± 7.82b 72.71 ± 7.05
WHR 0.95 ± 0.05b,d 0.87 ± 0.06d 0.89 ± 0.06b 0.80 ± 0.06
SBP (mmHg) 133.42 ± 17.79b,d 129.64 ± 17.93d 116.22 ± 15.97b 108.01 ± 14.66
DBP (mmHg) 89.82 ± 12.42b,d 85.29 ± 11.70d 77.75 ± 10.86b 72.13 ± 9.60
TG (mmol/L) 3.34 ± 2.23b,d 2.49 ± 1.27d 1.92 ± 1.30b 1.19 ± 0.68
TC (mmol/L) 4.90 ± 0.97d 4.95 ± 1.00d 4.58 ± 0.90b 4.28 ± 0.85
HDL-C (mmol/L) 1.08 ± 0.27b,d 1.21 ± 0.26d 1.30 ± 0.32b 1.49 ± 0.33
LDL-C (mmol/L) 2.56 ± 0.90b 2.69 ± 0.91d 2.50 ± 0.80b 2.29 ± 0.72
FPG (mmol/L) 5.61 ± 1.70d 5.64 ± 2.01d 4.86 ± 1.23b 4.69 ± 0.71
AST (U/L) 26.92 ± 11.40b,d 23.62 ± 10.86d 24.81 ± 10.57b 20.33 ± 7.37
ALT (U/L) 35.98 ± 21.69b,d 24.81 ± 17.82d 29.19 ± 21.86b 16.96 ± 12.20
AST/ALT ratio 0.92 ± 1.24b,d 1.12 ± 0.40d 1.03 ± 0.46b 1.41 ± 0.75
BMI: body mass index; WC: waist circumference; WHR: waist-hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure;
TG: triglycerides; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; FPG: fasting plasma
glucose.
a Significantly different from the female group is the male group with metabolic syndrome or no metabolic syndrome, all P < 0.05 or P < 0.01.
b Significantly different from the male group is the female group with metabolic syndrome or without metabolic syndrome after adjustment for
age, all P < 0.05 or P < 0.01.
c Significantly different from the male group or the female group with metabolic syndrome and without metabolic syndrome, all P < 0.05 or
P < 0.01.
d Significantly different from the male group or the female group with metabolic syndrome and without metabolic syndrome after adjustment for
age, all P < 0.05 or P < 0.01.
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(P ¼ 0.002 and 0.002 for the trend). In contrast, the
AST/ALT ratio decreased progressively with an
increasing number of MS components (P ¼ 0.017 for
trend). The incidence rates of elevated ASTwere 2.2%,Table 4
Metabolic variables in the study population with normal and elevated aspar
Variables Normal AST
(n ¼ 5135)
Elevated AST
(n ¼ 280)
t P
Percentage (%) 94.8 5.2
Age (years) 41.71 ± 11.60 40.86 ± 10.74 1.195 0.
BMI (kg$m2) 23.46 ± 3.27 25.17 ± 3.40a 8.494 <
WC (cm) 82.26 ± 10.56 88.48 ± 10.12a 9.996 <
WHR 0.87 ± 0.08 0.91 ± 0.07a 9.842 <
SBP (mmHg) 117.44 ± 18.54 122.69 ± 19.39a 4.608 <
DBP (mmHg) 78.55 ± 12.57 82.06 ± 12.93a 4.544 <
TG (mmol/L) 1.95 ± 1.53 2.84 ± 2.26a 6.538 <
TC (mmol/L) 4.55 ± 0.93 4.92 ± 1.03a 5.891 <
HDL-C (mmol/L) 1.32 ± 0.33 1.27 ± 0.47 1.920 0.
LDL-C (mmol/L) 2.44 ± 0.80 2.62 ± 0.91a 3.274 0.
FPG (mmol/L) 4.99 ± 1.32 5.15 ± 1.25 1.897 0.
BMI: body mass index; WC: Waist circumference; WHR: Waist-hip ratio
Triglycerides; TC: Total cholesterol; HDL: high-density lipoprotein cholest
glucose.
a Significantly different from the elevated group with normal AST and AL4.2%, 6.6%, and 8.0%, and were 5.1%, 12.1%, 18.5%,
and 26.8% for elevated rates of ALT in the subjects
with 0, 1, 2, and 3 risk factors, respectively. The
adjusted odds ratios for subjects with 1, 2, and 3 risk
factors were 1.67 (95%CI: 1.06e2.63), 2.28 (95%CI:tate aminotransferase (AST) and alanine aminotransferase (ALT).
Normal ALT
(n ¼ 4578)
Elevated ALT
(n ¼ 837)
t P
84.5 15.5
232 41.98 ± 11.86 39.97 ± 9.54a 5.372 <0.001
0.001 23.17 ± 3.20 25.62 ± 3.11a 20.793 <0.001
0.001 81.34 ± 10.43 89.37 ± 9.01a 23.104 <0.001
0.001 0.86 ± 0.08 0.91 ± 0.06a 20.292 <0.001
0.001 116.82 ± 18.44 122.59 ± 18.82a 8.296 <0.001
0.001 78.01 ± 12.45 82.68 ± 12.77a 9.944 <0.001
0.001 1.85 ± 1.48 2.81 ± 1.88a 13.969 <0.001
0.001 4.51 ± 0.92 4.89 ± 0.98a 11.024 <0.001
055 1.33 ± 0.34 1.20 ± 0.35a 10.356 <0.001
001 2.42 ± 0.79 2.61 ± 0.89a 5.636 <0.001
058 4.96 ± 1.19 5.25 ± 1.86a 4.433 <0.001
; SBP: Systolic blood pressure; DBP: Diastolic bloodpressure; TG:
erol; LDL: low-density lipoprotein cholesterol; FPG: Fasting plasma
T, all P < 0.05 or P < 0.01 (Student's t-test).
Table 5
The associations between each metabolic variable and the risk of elevated AST and ALT.
Items Overall Normal AST Elevated AST OR (95%CI) P-value Normal ALT Elevated ALT OR (95%CI) P-value
n ¼ 5415 n ¼ 5135 n ¼ 280 n ¼ 4578 n ¼ 837
Age 41.67 ± 11.56 41.71± 11.60 40.86± 10.74 41.98± 11.86 39.97 ± 9.54d
Genderd
Female 2097 (38.7) 2052 (40.0) 45 (16.1) 1 1996 (43.6) 101 (12.1) 1
Male 3318 (61.3) 3083 (60.0) 235 (83.9) 3.48 (2.51e4.85) <0.001 2582 (56.4) 736 (87.9) 6.23 (5.01e7.75) <0.001
BMId
<24 3009 (55.6) 2908 (56.6) 101 (36.1) 1 2762 (60.3) 247 (29.5) 1
24e27.9 1914 (35.3) 1792 (34.9) 122 (43.6) 1.96 (1.50e2.57) <0.001 1495 (32.7) 419 (50.1) 3.63 (3.05e4.33) <0.001
28 492 (9.1) 435 (8.5) 57 (20.4) 3.77 (2.69e5.30) <0.001 321 (7.0) 171 (20.4) 6.88 (5.46e8.69) <0.001
Abdominal obesitya 1965 (36.3) 1822 (35.5) 143 (51.5)d 1.90 (1.49e2.42) <0.001 1503 (32.8) 462 (55.2)d 3.08 (2.63e3.61) <0.001
Serum triglycerides
1.70 mmol/L
2408 (44.5) 2222 (43.3) 186 (66.4)d 2.59 (2.01e3.35) <0.001 1814 (39.6) 594 (71.0)d 4.30 (3.64e5.08) <0.001
Low serum HDL-Cb 1599 (29.5) 1517 (29.5) 82 (29.3) 0.99 (0.76e1.29) 0.927 1317 (28.8) 282 (33.7)d 1.26 (1.08e1.48) 0.004
High blood pressurec 1823 (33.7) 1696 (33.0) 127 (45.4)d 1.68 (1.32e2.15) <0.001 1441 (31.5) 382 (45.6)d 2.26 (1.93e2.65) <0.001
FPG 5.6 mmol/L 785 (14.5) 721 (14.0) 64 (22.9)d 1.81 (1.36e2.42) <0.001 592 (12.9) 193 (23.1)d 2.38 (1.96e2.87) <0.001
OR: odds ratio; CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein cholesterol; FPG: fasting plasma glucose; AST: aspartate aminotransferase; ALT: alanine
aminotransferase.
Note: continuous variables are means ± SD and categorical variables are numbers (%).
a Waist circumference 90 cm in males and 80 cm in females.
b Serum HDL-C <1.03 mmol/L in males and <1.30 mmol/L in females.
c Systolic blood pressure 130 mm Hg or diastolic blood pressure 85 mm Hg.
d Significantly different from the elevated group with normal AST and ALT, all P < 0.05 or P < 0.01 (Student's t-test or Pearson c2 test).
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AST and 2.02 (95%CI: 1.50e2.73), 2.68 (95%CI:
1.96e3.65), and 3.94 (95%CI: 2.86e5.43) for elevated
ALT. We observed a direct relationship between the
adjusted ORs of elevated AST and ALT and the pro-
portion of MS, and the linear trend was significant
(P ¼ 0.012, and 0.007 for trend).
Discussion
Recently, some studies have demonstrated that liver
enzymes are associated with risks of type 2 diabetes
mellitus, nonalcoholic fatty liver disease (NAFLD),
and MS in Western countries and developing coun-
tries.17,18 However, very little progress has been made
evaluating the adult population in China, especially in
the relatively undeveloped areas like Ningxia. The
purpose of our study was to investigate the impact of
elevated aspartate and alanine aminotransferase on MS
and its components among adults living in Ningxia,
China.
In this study, we report that the age-adjusted prev-
alence of MS is 23.2% in the study population ac-
cording to the modified ATPIII criteria for Asian
Americans by AHA-ATP III. The MS prevalence ob-
tained in our study is remarkably higher than what was
reported previously in a survey of rural adults in
Ningxia using the criteria of the International Diabetes
Federation IDF (2005).19 These findings showed that
the MS had become a serious public health challenge
in Ningxia. The prevalence of elevated AST and ALT
were higher in males (7.1% and 22.2%) compared with
females (2.1% and 4.8%), and our findings agree with
the results of previous studies.14,18
The association of aminotransferase levels with MS
or its constituents has already been reported. These
studies showed that hepatic enzyme levels in subjects
with MS were significantly higher than those in sub-
jects without the MS.2,13,17,20 Particularly, insulin
resistance studies showed not only the ALT level but
also the aminotransferase ratio might be used as a
marker for MS.21 Nevertheless, an ATTICA study has
reported an association of MS only with the AST/ALT
ratio.22 Our study demonstrates associations of MS
with AST, ALT, and the AST/ALT ratio. AST and ALT
concentrations were higher and the AST/ALT ratio
lower in those with MS in both males and females.
A few earlier studies have reported that the preva-
lence of elevated (abnormal) ALT or ALT levels de-
creases with increasing age in both genders.14,23,24
There are some reports of this association being
found in males but not in females.25,26 However, other
131K.-P. He et al. / Chronic Diseases and Translational Medicine 1 (2015) 124e132reports suggest that there is no correlation between
ALT and age.27,28 In our study, we found that the AST
and ALT levels and the prevalence of elevated
(abnormal) AST and ALT decreased with age in males
and increased in females. The mechanisms are still
unclear. A Rancho Bernardo Study reported that ALT
levels decreased with increased age in both men and
women independent of MS components, adiposity
signaling biomarkers, and other commonly used liver
function tests.23 They proposed that further studies
were needed to understand the mechanisms responsible
for a decline in ALT with age, and to establish the
optimal cut-point of normal ALT in the elderly. In the
present study, the serum ALT level is more closely
related to MS than AST level. So, our finding agrees
with the results of previous studies.29 The reason may
be that ALT has only low levels in skeletal muscle and
kidneys, so it is more specific for liver damage than
AST that is diffusely represented in the heart, skeletal
muscle, kidneys, brain, and red blood cells.22
We found a significant relationship between
elevated AST and ALT levels and the number of
components of MS after adjustment for age, gender
and BMI, although the odds ratio does not represent
the exact change of biological function. A Korean
study on adolescents revealed that the risks for elevated
ALT increased with the number of components of MS
after adjustment for age and body mass index.13 Our
results also showed that the AST and ALT levels in-
crease with the number of components of MS, whereas
the AST/ALT ratio decreases. However, the mean ALT
activities in subjects with 2 or 3 metabolic risk factors
were not particularly high, tending only to be close to
the upper limit. Screening for serum ALT levels may
facilitate identifying the potential risk for MS-related
diseases in the general population, in addition to
detection of liver disease, even within the reference
interval.30 Although this relationship between AST,
ALT and MS is not clearly understood, some mecha-
nisms, including the presence of oxidative stress and/or
NAFLD, can explain.
We are aware that the present data have some
limitations and should be interpreted with caution.
Our study used a cross-sectional design, so it could
not establish causal relationships, but our finding
agreed with hypotheses about the link between liver
enzymes and aminotransferase ratio and MS.22 Our
conclusions are based solely on liver enzymes levels,
whereas serum ALT and AST levels alone cannot be
used as a marker for histological diagnosis. The
population sample was selected from employees of
the local governments and industries of Ningxia, andmight not be represented the whole populations of
Ningxia. Furthermore, the threshold for defining
elevated hepatic enzymes in adults remains unclear.
Some studies reported that increased concentrations
of hepatic enzyme in serum, even within the refer-
ence interval, may be related to an increased risk of
MS.3,29
In conclusion, our study demonstrated that the
serum aminotransferases levels were higher in both
genders with MS and they were higher in males than
in females in adult groups from Ningxia, China,
whereas serum ALT level was more closely associated
with the MS than AST levels. The mean values of
serum aminotransferases decreased with increasing
age in males and increased in females. Our results
revealed that the risks for elevated aminotransferase
levels increased with the number of components of
MS after adjustment for age, gender, and BMI.
Moreover, our study also showed that with the
increased number of components of MS, the amino-
transferases level increases and the aminotransferases
ratio decreases.
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